Imagine a world where cutting-edge technology could revolutionize the way we treat prostate cancer, making it more precise and accessible to millions. But here's the catch: the very tools needed for this advancement are unevenly distributed across the globe. The International Atomic Energy Agency (IAEA) is stepping up to address this critical issue with a groundbreaking initiative.
In a bold move, the IAEA has launched a year-long coordinated research project aimed at developing CT-based contouring guidelines for prostate cancer, a pivotal step in radiation therapy. This project, starting in December 2025, brings together researchers worldwide to not only establish these guidelines but also to create and test an AI-driven contouring tool. This innovation could be a game-changer, especially in regions where advanced imaging equipment is scarce.
Prostate cancer is a global health crisis, with nearly 1.5 million new cases and 400,000 deaths reported in 2022 alone. It’s the fourth most common cancer worldwide and the eighth leading cause of cancer-related deaths. Among men, it ranks second in incidence and fifth in mortality. Alarmingly, projections indicate that by 2050, low- and middle-income countries will see over 1.37 million new cases annually, driven by aging populations and increased life expectancy.
Radiation therapy is a cornerstone of treatment for non-metastatic prostate cancer, as emphasized by May Abdel-Wahab, Director of the IAEA’s Division of Human Health. However, the Lancet Oncology Commission on Medical Imaging and Nuclear Medicine highlights a stark disparity: in low-income countries, one MRI scanner serves approximately 5.6 million people, compared to 145,000 in middle-income nations. And this is the part most people miss: CT scanners, which are three times more available in these regions, remain the primary tool for radiotherapy planning, despite their limitations in soft tissue contrast.
Here’s where it gets controversial: the reliance on CT scans for contouring can lead to inconsistencies in treatment planning. Seungtaek Choi, a professor at the University of Texas MD Anderson Cancer Center, points out that inferior soft tissue contrast makes it challenging to accurately delineate the prostate gland, resulting in inter-physician variability. Could this variability be compromising patient outcomes? Overestimated contouring volumes, for instance, can impact both treatment precision and patient survival rates.
To tackle these challenges, the IAEA is collaborating with leading cancer institutes, including the MD Anderson Cancer Center and Rays of Hope Anchor Centres, to develop CT-based contouring guidelines and an AI tool tailored for resource-limited settings. Soha Salem, the project’s primary investigator, explains that these guidelines will incorporate prostate and pelvic lymph node contouring protocols, addressing the unique needs of underserved regions. The goal? To reduce inter-observer variation, enhance contouring quality, and improve operational efficiency.
But here’s the bigger question: Can AI truly bridge the gap in global cancer care? While the potential is immense, the success of this initiative depends on widespread adoption and equitable access to technology. What do you think? Is AI the solution to global healthcare disparities, or are there deeper systemic issues at play?
This coordinated research project is open to all IAEA Member States. Research institutions interested in participating must submit their Proposal for Research Contract or Agreement by February 15, 2026, using the template available on the IAEA’s CRA web portal. The agency encourages the inclusion of women and young researchers in proposals. For more details, visit the CRP page or use the contact form provided.
The fight against prostate cancer is far from over, but with initiatives like this, we’re one step closer to a future where every patient, regardless of geography, receives the care they deserve. What role do you think technology should play in leveling the healthcare playing field?
